-- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Securities code: 688221 Securities abbreviation: Frontier Biotechnology Announcement number: 2025-035 Frontier Biopharmaceutical (Nanjing) Co., Ltd.

Announcement of Resolutions of the Second Extraordinary General Meeting of Shareholders in 2025

The company's board of directors and all directors guarantee that the announcement does not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.

Important content reminder:

 Whether any motions were rejected at this meeting: None

1. Meeting convening and attendance

(1) Time of the shareholders’ meeting: October 9, 2025

(2) The location of the shareholders’ meeting: Nanjing Jiayue Yinhu Hotel (No. 5, Lize Road, Jiangning Development Zone, Nanjing)

(3) Information on the ordinary shareholders, special voting rights shareholders, preference shareholders whose voting rights have been restored and the number of voting rights they hold present at the meeting:

1. Number of shareholders and proxies attending the meeting 156 Number of ordinary shareholders 156

2. Number of voting rights held by shareholders attending the meeting 169,708,958 Number of voting rights held by ordinary shareholders 169,708,958

3. The ratio of the number of voting rights held by shareholders attending the meeting to the number of voting rights of the company

45.3066 cases (%)

The proportion of the number of voting rights held by ordinary shareholders to the number of voting rights of the company (%) 45.3066

(4) Whether the voting method complies with the provisions of the "Company Law" and the company's articles of association, the status of the meeting, etc. Yes

(5) Attendance of the company’s directors, supervisors and board secretary

1. The company has 7 current directors, 6 of whom were present. Ms. Wang Sumei was unable to attend this meeting due to work reasons;

2. The company has 3 current supervisors and 3 persons present;

3. Ms. Gao Qianya, secretary of the board of directors, attended this meeting; senior manager Lu Hangzhou attended this meeting as a non-voting delegate

2. Proposal review status

(1) Non-cumulative voting proposals

1. Proposal Name: "Proposal Regarding the Company's 2025 Restricted Stock Incentive Plan (Draft)> and its Summary"

Review result: Passed

Voting status:

Agree Disagree Abstain

Type of shareholder Proportion Proportional number of votes Proportion (%) Number of votes Number of votes

(%) (%) Ordinary shares 168,866,019 99.5033 816,639 0.4811 26,300 0.0156

2. Proposal Name: "Proposal on the Company's Implementation Assessment and Management Measures for the 2025 Restricted Stock Incentive Plan"

Review result: Passed

Voting status:

Agree Disagree Abstain

Type of shareholder Proportion Proportional number of votes Proportion (%) Number of votes Number of votes

(%) (%) Ordinary shares 168,866,019 99.5033 816,639 0.4811 26,300 0.0156

3. Proposal Name: "Proposal on Proposing to the General Meeting of Shareholders to Authorize the Board of Directors to Handle Matters Related to the Company's Equity Incentive Plan"

Review result: Passed

Voting status:

Agree Disagree Abstain

Type of shareholder Proportion Proportional number of votes Proportion (%) Number of votes Number of votes

(%) (%) Ordinary shares 168,866,019 99.5033 816,639 0.4811 26,300 0.0156

(2) When major matters are involved, the voting status of less than 5% of shareholders should be explained.

Motion Agree Objection Abstain

Motion name

Serial number Number of votes Proportion (%) Number of votes Proportion (%) Number of votes Proportion (%)

"About the Company <2025 Restricted Stock

1 Incentive Plan (Draft)>Proposal and Summary 12,426,519 93.6475 816,639 6.1542 26,300 0.1983"

"About the Company <2025 Restricted Stock

2 Incentive Plan Implementation Assessment Management Measures> 12,426,519 93.6475 816,639 6.1542 26,300 0.1983 Proposal》

"About submitting a request to the general meeting of shareholders to authorize the board of directors

3 Handle matters related to the company’s equity incentive plan 12,426,519 93.6475 816,639 6.1542 26,300 0.1983

motion"

(3) Explanation of relevant circumstances regarding voting on motions

Proposals 1~3 are special resolution matters and were passed by more than two-thirds of the total number of shares with valid voting rights held by shareholders (including shareholders’ proxies) who have attended this shareholders’ meeting.

Proposals 1~3 carried out separate counting of votes for small and medium-sized investors.

3. Lawyer’s testimony

1. The law firm witnessing this general meeting of shareholders: Beijing Guofeng (Nanjing) Law Firm

Lawyers: Dai Wendong, Wang Jin

2. Lawyer’s concluding comments:

Our lawyers believe that the convening and convening procedures of this meeting of the company are in compliance with the provisions of laws, administrative regulations, rules, normative documents, "Rules for Shareholders' Meetings of Listed Companies" and "Articles of Association". The qualifications of the convener of this meeting and those attending the meeting, as well as the voting procedures and voting results of this meeting are legal and valid.

Announcement is hereby made.

Frontier Biopharmaceutical (Nanjing) Co., Ltd. Board of Directors October 10, 2025

 Reporting documents

(1) The resolution of the general meeting of shareholders signed and confirmed by the directors present and the recorder and stamped with the seal of the board of directors;

(2) A legal opinion signed by the director of the law firm and stamped with the official seal witnessed by the law firm;

(3) Other documents required by the Exchange.